ZBIO
What one share of Zenas BioPharma holds
Pharmaceutical Preparations
We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding
Zenas BioPharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$9.05 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.22 |
| Cash and investments | $3.10 |
| Debt | $3.52 |
| Book value | $3.90 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $32.65 | −$24.25 | $0.01 | −$19.95 | — | −$143.15 |
| 2024 | $0.38 | −$11.89 | $0.01 | −$9.08 | — | — |
| 2025 | $0.22 | −$8.44 | $0.00 | −$3.85 | — | $4.44 |